Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) Subsidiary Becomes Holder of上市 License for Amasulpiride Oral Dispersible Tablet

Stock News

2025/10/24

Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shon Pharmaceutical Co., Ltd. ("Shon Pharmaceutical"), has received a "Notice of Drug Supplement Application Approval" from the National Medical Products Administration, which allows the change of上市 license holder for Amasulpiride Oral Dispersible Tablet to Shanghai Shon Pharmaceutical Co., Ltd. The announcement states that Amasulpiride Oral Dispersible Tablet is an improved dosage form of Amasulpiride, which was launched by Sanofi in France in 1986, and is used for treating adult schizophrenia. In September 2025, Shon Pharmaceutical submitted a registration application for the change of the drug's上市 license holder to the National Medical Products Administration, which has been accepted.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1127558805"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1127558805\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1127558805?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-24 15:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1127558805","market":"sh","top_or_hot":-1,"title":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) Subsidiary Becomes Holder of上市 License for Amasulpiride Oral Dispersible Tablet","media":"Stock News","content":"<p>Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shon Pharmaceutical Co., Ltd. (\"Shon Pharmaceutical\"), has received a \"Notice of Drug Supplement Application Approval\" from the National Medical Products Administration, which allows the change of上市 license holder for Amasulpiride Oral Dispersible Tablet to Shanghai Shon Pharmaceutical Co., Ltd. The announcement states that Amasulpiride Oral Dispersible Tablet is an improved dosage form of Amasulpiride, which was launched by Sanofi in France in 1986, and is used for treating adult schizophrenia. In September 2025, Shon Pharmaceutical submitted a registration application for the change of the drug's上市 license holder to the National Medical Products Administration, which has been accepted.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) Subsidiary Becomes Holder of上市 License for Amasulpiride Oral Dispersible Tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) Subsidiary Becomes Holder of上市 License for Amasulpiride Oral Dispersible Tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-24 15:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shon Pharmaceutical Co., Ltd. (\"Shon Pharmaceutical\"), has received a \"Notice of Drug Supplement Application Approval\" from the National Medical Products Administration, which allows the change of上市 license holder for Amasulpiride Oral Dispersible Tablet to Shanghai Shon Pharmaceutical Co., Ltd. The announcement states that Amasulpiride Oral Dispersible Tablet is an improved dosage form of Amasulpiride, which was launched by Sanofi in France in 1986, and is used for treating adult schizophrenia. In September 2025, Shon Pharmaceutical submitted a registration application for the change of the drug's上市 license holder to the National Medical Products Administration, which has been accepted.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0175","symbol_name":"白马股","start_time":0,"source_url":"","article_id":"1127558805","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1127558805","pubTimestamp":1761291737,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shon Pharmaceutical Co., Ltd. (\"Shon Pharmaceutical\"), has received a \"Notice of Drug Supplement...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601607":"上海医药","BK0175":"白马股","BK0012":"证金概念","BK0187":"一线龙头","BK0196":"行业龙头","BK0184":"上海国资改革","02607":"上海医药","BK0028":"国家队","BK0209":"零售","BK0097":"医药电商","BK0099":"上海本地重组","BK0020":"浦东新区","BK1197":"保健护理产品经销商","BK0183":"MSCI概念","BK0188":"融资融券"},"translate_title":"上海医药控股股份有限公司（601607.SH）子公司成为氨磺必利口服分散片上市许可持有人","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":1,"02607":1},"content_text":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shon Pharmaceutical Co., Ltd. (\"Shon Pharmaceutical\"), has received a \"Notice of Drug Supplement Application Approval\" from the National Medical Products Administration, which allows the change of上市 license holder for Amasulpiride Oral Dispersible Tablet to Shanghai Shon Pharmaceutical Co., Ltd. The announcement states that Amasulpiride Oral Dispersible Tablet is an improved dosage form of Amasulpiride, which was launched by Sanofi in France in 1986, and is used for treating adult schizophrenia. In September 2025, Shon Pharmaceutical submitted a registration application for the change of the drug's上市 license holder to the National Medical Products Administration, which has been accepted.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}